Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options

Frontiers in Cardiovascular Medicine

Volumn 6, Issue , 2019, Pages

  Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

endomyocardial biopsy; immunohistology; immunopathogenesis; immunosuppressive therapy; ivIg; myocarditis; PCR of cardiotropic viruses

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; PATHOGEN ASSOCIATED MOLECULAR PATTERN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; CARDIAC SARCOIDOSIS; CARDIOMYOPATHY; EOSINOPHIL; GENE DELETION; GENOTYPE; HEART MUSCLE BIOPSY; HUMAN; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOHISTOLOGY; LEUKOCYTE; MYOCARDITIS; REVIEW; SARCOLEMMA; STEM CELL TRANSPLANTATION; TH1 TH2 BALANCE;

EID: 85079199419     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2019.00048     Document Type: Review

References (122)

1. Kerr WW. Myocarditis. Cal State J Med. (1904) 2:369–71.
2. Maisch B, Trostel-Soeder R, Stechemesser E, Berg PA, Kochsiek K. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol. (1982) 48:533–45. 6288291
3. Linde A, Mosier D, Blecha F, Melgarejo T. Innate immunity and inflammation— new frontiers in comparative cardiovascular pathology. Cardiovasc Res. (2007) 73:26–36. 10.1016/j.cardiores.2006.08.00917010957
4. Portig I, Pankuweit S, Maisch B. Antibodies against stress proteins in the sera of patients with dilated cardiomyopathy. J Mol Cell Cardiol. (1997) 29:2245–51. 10.1006/jmcc.1997.04639281455
5. Wicks EC, Elliott PM. Genetics and metabolic cardiomyopathies. Herz. (2012) 37:598–611. 10.1007/s00059-012-3659-022936369
6. Kloos W, Katus HA, Meder B. Genetic cardiomyopathies. Lessons learned from humans, mice, and zebrafish. Herz. (2012) 37:612–8. 10.1007/s00059-012-3651-822767018
7. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial disease. Eur Heart J. (2007) 29:270–6. 10.1093/eurheartj/ehm342
8. Caforio A, Pankuweit S, Charron P, et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. (2013) 34:2636–48. 10.1093/eurheartj/eht21023824828
9. Maisch B, Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. Herz. (2012) 37:644–56. 10.1007/s00059-012-3679-922996288
10. Maisch B, Alter P. Treatment options in myocarditis and inflammatory cardiomyopathy. Focus on i.v. immunoglobulins. Herz. (2018) 43:423–30. 10.1007/s00059-018-4719-x29947834
11. Hickie JB, Hall GV. The cardiomyopathies: a report of fifty cases. Australas Ann Med. (1960) 9:258–70. 10.1111/imj.1960.9.4.25813714127
12. Anonymous. Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J. (1980) 44:672–74. 10.1136/hrt.44.6.672
13. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. (1996) 93:841–2. 10.1161/01.CIR.93.5.8418598070
14. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. (1987) 18:619–24. 10.1016/S0046-8177(87)80363-53297992
15. Maisch B, Bültmann B, Factor S, Groene HJ, Hufnagel G, Kawarmura K, et al. World Heart Federation consensus conferences's definition of inflammatory cardiomyopathy (myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat. (1999) 4:3–4.
16. Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. Herz. (2000) 25:200–9. 10.1007/s00059005000710904839
17. Pankuweit S, Portig I, Eckhardt H, Crombach M, Hufnagel G, Maisch B. Prevalence of viral genome in endomyocardial biopsies from patients with inflammatory heart muscle disease. Herz. (2000) 25:221–6. 10.1007/s00059005001010904842
18. Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. (2018) 18:733–44. 10.1038/s41577-018-0065-830228378
19. Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages facilitate electrical conduction in the heart. Cell. (2017) 169:510–22. 10.1016/j.cell.2017.03.05028431249
20. Horckmans M, Bianchini M, Santovito D, Megens RTA, Springael JY, Negri I, et al. Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction. Circulation. (2018) 137:948–60. 10.1161/CIRCULATIONAHA.117.02883329167227
21. Butts B, Lee A, Goeddel LA, George DJ, Steele C, Davies JE, et al. Increased inflammation in pericardial fluid persists 48 hours after cardiac surgery. Circulation. (2017) 136:2284–6. 10.1161/CIRCULATIONAHA.117.02958929203568
22. Lévêque N, Garcia M, Bouin A, Nguyen JHC, Tran GP, Andreoletti L, et al. Functional consequences of RNA 5 = -terminal deletions on coxsackievirus B3 RNA replication and ribonucleoprotein complex formation. J Virol. (2017) 91:e00423–17. 10.1128/JVI.00423-1728539455
23. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in BALB/c mice: evidence for autoimmunity to myocyte antigens. J Pathol. (1984) 116:21–9. 6331168
24. Rose NR, Wolfgram LJ, Herskowitz A, Beisel KW. Postinfectious autoimmunity: two distinct phases of Coxsackievirus B3-induced myocarditis. Ann N Y Acad Sci. (1986) 475:146–56. 10.1111/j.1749-6632.1986.tb20864.x3024549
25. Rose NR. Critical cytokine pathways to cardiac inflammation. J Interferon Cytok Res. (2011) 31:705–9. 10.1089/jir.2011.005721861699
26. Huber S, Ramsingh AI. Coxsackievirus-induced pancreatitis. Viral Immunol. (2004) 17: 358–69. 10.1089/vim.2004.17.35815357902
27. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. (2013) 13:397–411. 10.1038/nri345223702978
28. Maisch B, Deeg P, Liebau G, Kochsiek K. Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol. (1983) 52:1072–8. 10.1016/0002-9149(83)90535-06356861
29. Maisch B, Bauer E, Cirsi M, Kochsiek K. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation. (1993) 87:49–65. 8485834
30. Maisch B. The sarcolemma as antigen in the secondary immunopathogenesis of myopericarditis. Eur Heart J. (1987) 8(Suppl J):155–65. 10.1093/eurheartj/8.suppl_J.155
31. Pankuweit S, Portig I, Lottspeich F, Maisch B. Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. J Mol Cell Cardiol. (1997) 29:77–84. 10.1006/jmcc.1996.02539040023
32. Maisch B, Wedeking U, Kochsiek K. Quantitative assessment of antilaminin antibodies in myocarditis and perimyocarditis. Eur Heart J. (1987) 8(Suppl J):223–35. 10.1093/eurheartj/8.suppl_J.233
33. Obermayer U, Scheidler J, Maisch B. Antibodies against micro- and intermediate filaments in carditis and dilated cardiomyopathy - are they a diagnostic marker? Eur Heart J. (1987) 8(Suppl. J):181–6. 10.1093/eurheartj/8.suppl_J.181
34. Klein R, Maisch B, Kochsiek K, Berg PA. Demonstration of organ specific antibodies against heart mitochondria (anti M7) in sera from patients with some forms of heart diseases. J Clin Exp Immunol. (1984) 58:283–92. 6238732
35. Pohlner K, Portig I, Pankuweit S, Lottspeich F, Maisch B. Identification of mitochondrial antigens recognized by the antibodies in sera of patients with dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol. (1997) 80:1040–5. 10.1016/S0002-9149(97)00600-09352975
36. Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. (2008) 41:35–45. 10.1080/0891693070161923518176863
37. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res. (2012) 110:145–58. 10.1161/CIRCRESAHA.111.24336022223211
38. Wallukat G, Wollenberg A, Morwinski R, Pitschner HF. Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol. (1995) 27:3977–4006. 10.1016/S0022-2828(08)80036-3
39. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F, et al. Autoantibodies activating human beta 1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. (1999) 99:649–54. 10.1161/01.CIR.99.5.649
40. Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, et al. Localization of a functional autoimmune epitope on the second extracellular loop of the human muscarinic acetylcholin receptor 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest. (1993) 91:1964–8. 10.1172/JCI116416
41. Maisch B, Lotze U, Schneider J, Kochsiek K. Antibodies to human sinus node in sick-sinus syndrome. Pacing Clin Electrophysiol. (1986) 9:1101–9. 10.1111/j.1540-8159.1986.tb06677.x2432516
42. Lotze U, Maisch B. Humoral immune response to cardiac conducting tissue. Springer Semin Immunopathol. (1989) 11:409–22. 10.1007/BF002018792694408
43. Maisch B. Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury. Springer Semin Immunopathol. (1989) 11:369–95. 10.1007/BF002018772694406
44. Goin JC, Borda ES, Auger S, Storino R, Sterin-Borda L. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia. Heart. (1999) 82:273–8. 10.1136/hrt.82.3.27310455074
45. Schultheiss HP, Bolte HD. Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol. (1988) 17:603–17. 10.1016/S0022-2828(85)80029-8
46. Limas CJ, Limas C, Kubo SH, Olivari MT. Anti-β-receptor antibodies in human dilated cardiomyopathy and correlation with HLA-DR antigens. Am J Cardiol. (1990) 65:483–7. 10.1016/0002-9149(90)90815-I2154917
47. Jahns R, Bolvin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a ß1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. (2004) 113:1419–29. 10.1172/JCI200420149
48. Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. Ann Rev Immunol. (1993) 11:79–104. 10.1146/annurev.iy.11.040193.0004558476578
49. Wolff PG, Kühl U, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J. (1989) 117:1303–9. 2658521
50. Ansari AA, Wang YC, Danner DJ, Gravanis MB, Mayne A, Neckelmann N, et al. Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy. Am J Pathol. (1991) 139:337–54. 1867322
51. Wittner B, Maisch B, Kochsiek K. Quantification of antimyosin antibodies in experimental myocarditis by a new solid-phase fluorometric assay. J Immunol Methods. (1983) 64:239–47. 10.1016/0022-1759(83)90402-76417242
52. Caforio AL, Goldman JH, Haven AJ, Baig KM, McKenna WJ. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol. (1996) 54:157–63. 10.1016/0167-5273(96)02593-48803680
53. Göser S, Andrassy M, Buss S, Leuschner F, Volz CH, Ottl R, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. (2006) 114:1693–702. 10.1161/CIRCULATIONAHA.106.635664
54. Herzum M, Maisch B, Kochsiek K. Circulating immune complexes in perimyocarditis and infective endocarditis. Eur Heart J. (1987) 8(Suppl. J):323–6. 10.1093/eurheartj/8.suppl_J.323
55. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. (2012) 21:245–74. 10.1016/j.carpath.2011.10.00122137237
56. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol. (2012) 59:779–92. 10.1016/j.jacc.2011.09.07422361396
57. Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet. (2012) 379:738–47. 10.1016/S0140-6736(11)60648-X22185868
58. Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S, BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. (2005) 30:535–44. 10.1007/s00059-005-2730-516170686
59. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. (2008) 29:2073–82. 10.1093/eurheartj/ehn29618617482
60. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol. (2003) 34:497–503. 10.1016/S0046-8177(03)00078-912792925
61. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. (2010) 362:1248–9. 10.1056/NEJMc091136220357294
62. Maisch B. Effusive-constrictive pericarditis: current perspectives. J Cardiovasc Diagn Interv. (2018) 6:7–14. 10.2147/JVD.S125950
63. Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med. (2018) 215:827–40. 10.1084/jem.2017222229432122
64. De Rosa S, Eposito F, Carella C, Strangio A, Ammirati G, Sabatino J, et al. Transcoronary concentration gradients of circulating microRNAs in heart failure. Eur J Heart Fail. (2018) 20:1000–10. 10.1002/ejhf.111929314582
65. Waagstein F, Hjalmarson A, Varnauskas E, Walentin L. Effect of beta-adrenergic receptor blockade in congestive cardiomyoapthy. Br Heart J. (1975) 37:1022–36. 10.1136/hrt.37.10.10221191416
66. Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y, et al. Guidelines on the diagnosis and management of pericardial diseases, executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J. (2004) 25:587–610. 10.1016/j.ehj.2004.02.00215120056
67. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. (2015) 36:2921–61. 10.1093/eurheartj/ehv318
68. Costanzo-Nordin MR, Reap EA, O'Connell JB, Robinson JA, Scanlon PJ. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol. (1985) 6:1078–82. 10.1016/S0735-1097(85)80312-02995470
69. Maisch B. Management von Perikarditis und Perikarderguss, konstriktiver und effusiv-konstriktiver Perikarditis. Herz. (2018) 43:663–78.
70. Maisch B, Hufnagel G, Schönian U, Hengstenberg C. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J. (1995) 16:173–5. 8682090
71. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. (1990) 57:250–62. 10.1016/0090-1229(90)90039-S2208806
72. Cooper LT, Berry GHJ, Shabetai R. Giant cell myocarditis: distinctions from lymphocytic myocarditis and cardiac sarcoidosis. J Heart Fail. (1997) 4:227230.
73. Cooper LT, Okura Y. Idiopathic giant cell myocarditis. Current treatment options. Cardiovasc Med. (2001) 3:463–7. 10.1007/s11936-001-0020-y
74. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant cell myocarditis - natural history and treatment. N Engl J Med. (1997) 336:1860–6. 10.1056/NEJM1997062633626039197214
75. Fenoglio JJ, Ursell PC, Kellogg CF, Drusin RE, Weiss MB. Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med. (1983) 308:12–18. 10.1056/NEJM1983010630801036860402
76. Hosenpud JD, McAnulty JH, Niles NR. Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone. J Am Coll Cardiol. (1985) 6:797–801. 10.1016/S0735-1097(85)80485-X4031294
77. Anderson JL, Fowles RE, Unverferth DV, Mason JW. Immunosuppressive therapy of myocardial inflammatory disease. Initial experience and future trials to define indications for therapy. Eur Heart J. (1987) 8(Suppl J):263–6.
78. Marboe CC, Fenoglio JJ. Pathology and natural history of human myocarditis. Pathol Immunopathol Res. (1988) 7:226–39. 3070526
79. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J. (1989) 117:876–82. 10.1016/0002-8703(89)90626-12929404
80. Maisch B, Schoenian U, Hengstenberg C, Herzum M, Hufnagel G, Bethge C, et al. Immunosuppressive therapy in autoreactive myocarditis: results from a controlled trial. Postgrad Med J. (1994) 70(Suppl. 1):S29–34.
81. Jühl U, Strauer BE, Schultheiss HP. Methylprednisolone in chronic myocarditis. Postgrad Med J. (1994) 70(Suppl. 1):S35–42. 7971647
82. Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati M, et al. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol. (1995) 16:61–8. 10.1007/BF007968197784236
83. Liu D, Lei Y, Haixia J. Clinical search of Sheng Mai injection combined with corticosteroids for acute viral myocarditis in children. J Sichuan Tradit Chin Med. (2003) 21:59–60.
84. Sun D. Corticosteroid treatment effects in 36 cases diagnose with viral myocarditis with ventricle premature beats. J Zhenjiang Med Coll. (1999) 9:211–14.
85. Wu Y-Z, Chen B-W. Observation on curative effects of astragalus injection combined with glucocorticoids on acutely severe viral myocarditis. Zhongguo Zhong Xe Yi Jie He Ji Jui Za Zhi. (1999) 6:350–2.
86. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile for responders versus nonresponders. Circulation. (2003) 107:857–63. 10.1161/01.CIR.0000048147.15962.3112591756
87. Escher F, Kühl U, Lassner D, Poller W, Westermann D, Pieske B, et al. Long-term outcome of patients with virus negative chronic myocarditis or inflammatory cadiomyopathy after immunosuppressive therapy. Clin Res Cardiol. (2016) 105:1011–20. 10.1007/s00392-016-1011-z27312326
88. Parillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. (1989) 321:1061–8. 10.1056/NEJM198910193211601
89. Mason JW, O'Connel JB, Hershkowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med. (1995) 33:269–75.
90. Maisch B, Camerini F, Schultheiss H-P. Immunosuppressive therapy for myocarditis (letter). N Engl J Med. (1995) 333:1713.
91. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation. (2001) 104:39–45. 11435335
92. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. (2009) 30:1995–2002. 10.1093/eurheartj/ehp24919556262
93. Maisch B, Kölsch S, Hufnagel G, et al. for the ESETCID Investigators. Orlando 2011, AHA Congress. Circulation. (2011) Suppl (Abstract).
94. Hufnagel G, Maisch B, Pfeiffer U. Immunhistologic investigations in suspected cardiac sarcoidosis. Eur Heart J. (1987) 8(Suppl. J):59–62. 10.1093/eurheartj/8.suppl_J.59
95. Schoppet M, Pankuweit S, Moll R, Baandrup U, Maisch B. Images in cardiovascular medicine. Phenotype of infiltrating T lymphocytes in cardiac sarcoidosis. Circulation. (2002) 105:e67–8. 11914265
96. Valentonye R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice mutant in BTNL2. Nat Genet. (2005) 37:357–64. 10.1038/ng1519
97. Meyer T, Lauschke J, Ruppert V, Richter A, Pankuweit S, Maisch B. Isolated cardiac sarcoidosis associated with the expression of a splice variant coding for a truncated BTNL2 protein. Cardiology. (2008) 109:117121. 10.1159/00010555217703092
98. Bargout R, Kelly RF. Sarcoid heart disease. Clinical course and treatment. Int J Cardiol. (2004) 97:173–82. 10.1016/j.ijcard.2003.07.02415458680
99. Spry CJ, Tai PC, Davies J. The cardiotoxicity of eosinophils. Postgrad Med J. (1983) 59:147–55. 10.1136/pgmj.59.689.1476844197
100. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. (1987) 21:643–47. 10.1016/S0140-6736(87)90412-0
101. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant Ig Fc. Science. (2008) 320:373–376. 10.1126/science.1154315
102. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model–antiviral and anti-inflammatory effects. Circulation. (1995) 92:1604–11. 10.1161/01.CIR.92.6.16047664447
103. Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. (1995) 345:660–1. 10.1016/S0140-6736(95)90569-37898219
104. Walpen AJ, Laumonier T, Aebi C, Mohacsi PJ, Rieben R. IgM enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bacterial killing by human serum. Xenotransplantation. (2004) 11:141–8. 10.1046/j.1399-3089.2003.00098.x
105. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. (1994) 89:252–7. 10.1161/01.CIR.89.1.2528281654
106. McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, et al. Intravenous immune gobulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. (1997) 95:2476–8. 9184576
107. Takeda Y, Yasuda S, Miyazaki S, Daikoku S, Nakatani S, Nonogi H. High-dose immunoglobulin G therapy for fulminant myocarditis. Jap Circ J. (1998) 62:871–2. 10.1253/jcj.62.8719856608
108. Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D'Amati G, et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis. (2000) 31:65–9. 10.1086/31392910913398
109. Tsai YG, Ou TY, Wang CC, Tsai MC, Yuh YS, Hwang B. Intravenous gamma-globulin therapy in myocarditis complicated with complete heart block: report of one case. Chung-Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Ts Chih. (2001) 42:311–3. 11729711
110. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, et al. Controlled trial of intravenous immune globuline in recent-onset dilated cardiomyopathy. Circulation. (2001) 103:2254–549. 10.1161/01.CIR.103.18.225411342473
111. Alter P, Grimm W, Maisch B. Varicella myocarditis in an adult. Heart. (2001) 85:E2. 10.1136/heart.85.1.e211119480
112. Shioji K, Kishimoto C, Sasyama S. Immunoglobulin therapy for acute myocarditis. Resp Circul. (2000) 48:1133–9. 10.1161/01.CIR.95.11.2476
113. Tedeschi A, Airaghi L, Giannini S, Ciceri L, Massari FM. High-dose intravenous immunoglobulin in the treatment of acute myocarditis. A case report and review of the literature. J Intern Med. (2002) 251:169–73. 11905592
114. Kishimoto C, Fujita M, Kinoshita M, Iwase T, Tamaki S, Fujii M, et al. Immunglobulin therapy for myocarditis an acute dilated cardiomyopathy. Circulation. (2001) 103:220–5.
115. Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J. (2004) 23:275–6. 10.1097/01.inf.0000115950.63906.7815014311
116. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antiviral Ther. (2010) 15:193–201. 10.3851/IMP151620386074
117. Maisch B, Pankuweit S, Funck R, Koelsch S. Effective CMV hyperimmunoglobulin treatment in CMV myocarditis – A controled treatment trial. Eur Heart J. (2004) 25(Suppl.):114. 10.1016/S0735-1097(16)31348-1
118. Klugman D, Berger JT, Sable CA, He J, Khandelwal SG, Slonim AD. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol. (2009) 31:222–8. 10.1007/s00246-009-9589-919936586
119. Müller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. (2000) 101:385–91. 10653829
120. Wallukat G, Müller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med. (2002) 347:1806. 10.1056/NEJM20021128347222012456865
121. Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventriclar function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. (2003) 107:2793–8. 10.1161/01.CIR.0000072766.67150.51
122. Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. (2016) 105:763–3. 10.1007/s00392-016-0986-927112783